Hematologia

Amplo estudo revela os fatores de risco para insuficiência cardíaca entre crianças que sobreviveram ao câncer.

13 Set, 2022 | 11:41h

Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors – Journal of Clinical Oncology

Revisão sistemática | Estabilizadores de HIF (Hypoxia‐Inducible Factor) para a anemia na doença renal crônica.

12 Set, 2022 | 11:25h

Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease – Cochrane Library

Resumo: Are hypoxia-inducible factor stabilisers effective for management of anaemia among people with chronic kidney disease? – Cochrane Library

Estudo randomizado | Lenalidomida-dexametasona vs. observação no mieloma latente de alto risco após 12 anos de seguimento médio.

12 Set, 2022 | 11:24h

Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study – European Journal of Cancer (link para o resumo – $ para o texto completo)

Seguimento de 48 semanas de um estudo randomizado | Pegcetacoplan vs. eculizumabe em pacientes com hemoglobinúria paroxística noturna.

12 Set, 2022 | 11:16h

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial – The Lancet Haematology (link para o resumo – $ para o texto completo)

Estudo original: Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria – New England Journal of Medicine

Comentário no Twitter (fio – clique para saber mais)

NEW research—Duration of improved haem outcomes and favourable safety over 48 weeks suggests that pegcetacoplan has the potential to alter treatment goals in patients with paroxysmal nocturnal haemoglobinuria: long-term results of PEGASUS #PNH https://t.co/dpT5cDih8X

— The Lancet Haematology (@TheLancetHaem) September 1, 2022

Opinião | Ácido tranexâmico para uma cirurgia mais segura: o momento é agora.

8 Set, 2022 | 14:21h

Tranexamic acid for safer surgery: the time is now – British Journal of Surgery

Conteúdos relacionados:

#ACC22 – RCT: Tranexamic acid reduces the risk of bleeding in patients undergoing noncardiac surgery.

Update on applications and limitations of perioperative tranexamic acid.

RCT | Effect of high- vs. low-dose tranexamic acid infusion on need for red blood cell transfusion and adverse events in patients undergoing cardiac surgery.

Safety of tranexamic acid in hip and knee arthroplasty in high-risk patients – this large observational study did not show an increased risk for venous thromboembolism, myocardial infarction, seizures, ischemic strokes, or transient ischemic attacks, irrespective of patient high-risk status at baseline

M-A: Intravenous tranexamic acid in surgical patients is not associated with increased risk of thromboembolic events and mortality

Revisão | Diagnóstico e tratamento de síndromes mielodisplásicas.

8 Set, 2022 | 14:17h

Diagnosis and Treatment of Myelodysplastic Syndromes: A Review – JAMA (gratuito por tempo limitado)

Revisão clínica em áudio: Diagnosis and Management of Myelodysplastic Syndromes – JAMA

Estudo de coorte | Determinantes clínicos e moleculares da evolução clonal na anemia aplástica e na hemoglobinúria noturna paroxística.

8 Set, 2022 | 14:09h

Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

Comentário do autor no Twitter (fio – clique para saber mais)

Super excited to share our multicenter study on clonal evolution in 1008 patients with AA/PNH followed for a median f-up of 9 yrs now out in @JCO_ASCO https://t.co/j9U2ZjYX0o

— Carmelo Gurnari (@CarmeloGurnari) September 2, 2022